{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:44:08Z","timestamp":1790401448181,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir binds to paired helical filament tau and accurately identifies tau in Alzheimer\u2019s disease (AD). However, \u201coff-target\u201d binding interferes with the quantification of [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir in several brain regions. Recently, other tau PET tracers have been developed. Here, we compare [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir with the novel tau tracer [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 head-to-head in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 18 participants with AD, three with amyloid-\u03b2-positive amnestic mild cognitive impairment, and four healthy controls. All underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir (80\u2013100\u00a0min) and [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 (70\u201390) PET scans within approximately 1\u00a0month. Four study participants underwent 0\u2013100-min dynamic scanning. Standardized uptake value ratios (SUVRs) were created using an inferior cerebellar reference region.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Neocortical tracer retention was highly comparable using both SUVR and distribution volume ratio-1 values obtained from dynamic scans. However, [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 retention was significantly higher in the entorhinal cortex and lower in the basal ganglia, thalamus, and choroid plexus compared with [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir. Increased off-target binding was observed with age for both tracers. Several cases exhibited strong [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 retention in the skull\/meninges. This extra-cerebral signal, however, did not affect diagnostic accuracy and remained relatively unchanged when re-examining a subsample after 1\u00a0year. Kinetic modeling showed an increase in [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir SUVR over the scanning interval, compared with a plateau for [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir bound comparably in neocortical regions, but [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 showed higher retention in the medial temporal lobe and lower intracerebral \u201coff-target\u201d binding. Time-dependent bias of SUVR estimates may prove less of a factor with [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948, compared with previous tau ligands.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-019-04496-0","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T08:04:19Z","timestamp":1571040259000},"page":"342-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0112","authenticated-orcid":false,"given":"Ruben","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Leuzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"J\u00f6gi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"4496_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"4496_CR2","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4496_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","volume":"12","author":"K Iqbal","year":"2016","unstructured":"Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12:15\u201327. \nhttps:\/\/doi.org\/10.1038\/nrneurol.2015.225\n\n.","journal-title":"Nat Rev Neurol"},{"key":"4496_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367. \nhttps:\/\/doi.org\/10.1093\/brain\/aww027\n\n.","journal-title":"Brain."},{"key":"4496_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/JAD-151004","volume":"51","author":"R Smith","year":"2016","unstructured":"Smith R, Wibom M, Olsson T, Hagerstrom D, Jogi J, Rabinovici GD, et al. Posterior accumulation of tau and concordant hypometabolism in an early-onset Alzheimer\u2019s disease patient with presenilin-1 mutation. J Alzheimers Dis. 2016;51:339\u201343. \nhttps:\/\/doi.org\/10.3233\/JAD-151004\n\n.","journal-title":"J Alzheimers Dis"},{"key":"4496_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","volume":"87","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87:375\u201383. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000002892\n\n.","journal-title":"Neurology."},{"key":"4496_CR7","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92:e601\u2013e12. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000006875\n\n.","journal-title":"Neurology."},{"key":"4496_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/nen.0b013e31815c5efb","volume":"66","author":"PT Nelson","year":"2007","unstructured":"Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles \"do count\" when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136\u201346. \nhttps:\/\/doi.org\/10.1097\/nen.0b013e31815c5efb\n\n.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"4496_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"Antoine Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019. \nhttps:\/\/doi.org\/10.1038\/s41380-018-0342-8\n\n.","journal-title":"Molecular Psychiatry"},{"key":"4496_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93\u20139. \nhttps:\/\/doi.org\/10.2967\/jnumed.118.209650\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457\u201368. \nhttps:\/\/doi.org\/10.3233\/JAD-122059\n\n.","journal-title":"J Alzheimers Dis"},{"key":"4496_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","volume":"57","author":"R Harada","year":"2016","unstructured":"Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208\u201314. \nhttps:\/\/doi.org\/10.2967\/jnumed.115.164848\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2967\/jnumed.115.160127","volume":"56","author":"Y Kimura","year":"2015","unstructured":"Kimura Y, Ichise M, Ito H, Shimada H, Ikoma Y, Seki C, et al. PET quantification of tau pathology in human brain with 11C-PBB3. J Nucl Med. 2015;56:1359\u201365. \nhttps:\/\/doi.org\/10.2967\/jnumed.115.160127\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR14","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1007\/s00259-013-2553-1","volume":"41","author":"N Okamura","year":"2014","unstructured":"Okamura N, Furumoto S, Harada R, Tago T, Iwata R, Tashiro M, et al. Characterization of [18F]THK-5351, a novel PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:S260.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4496_CR15","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.118.209916","volume":"59","author":"DF Wong","year":"2018","unstructured":"Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, et al. Characterization of 3 novel tau radiopharmaceuticals, (11)C-RO-963, (11)C-RO-643, and (18)F-RO-948, in healthy controls and in Alzheimer subjects. J Nucl Med. 2018;59:1869\u201376. \nhttps:\/\/doi.org\/10.2967\/jnumed.118.209916\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"CF Xia","year":"2013","unstructured":"Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimers Dement. 2013;9:666\u201376. \nhttps:\/\/doi.org\/10.1016\/j.jalz.2012.11.008\n\n.","journal-title":"Alzheimers Dement"},{"key":"4496_CR17","unstructured":"Seibyl J, Barret O, Stephens A, Madonia J, Alagille D, Mueller A, et al. First in human characterization of PI-2620, a next generation PET tracer for assessing tau in Alzheimer\u2019s disease and other tauopathies. International Conference of Alzheimers and Parkinsons Disease. 2017:Page 224."},{"key":"4496_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4:58. \nhttps:\/\/doi.org\/10.1186\/s40478-016-0315-6\n\n.","journal-title":"Acta Neuropathol Commun"},{"key":"4496_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marquie","year":"2015","unstructured":"Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787\u2013800. \nhttps:\/\/doi.org\/10.1002\/ana.24517\n\n.","journal-title":"Ann Neurol"},{"key":"4496_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","volume":"12","author":"K Sander","year":"2016","unstructured":"Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, et al. Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12:1116\u201324. \nhttps:\/\/doi.org\/10.1016\/j.jalz.2016.01.003\n\n.","journal-title":"Alzheimers Dement"},{"key":"4496_CR21","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/brain\/aww163","volume":"139","author":"R Smith","year":"2016","unstructured":"Smith R, Puschmann A, Scholl M, Ohlsson T, van Swieten J, Honer M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139:2372\u20139. \nhttps:\/\/doi.org\/10.1093\/brain\/aww163\n\n.","journal-title":"Brain."},{"issue":"3","key":"4496_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","volume":"76","author":"Ruben Smith","year":"2019","unstructured":"Smith R, Wibom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo [18F]Flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 2018. \nhttps:\/\/doi.org\/10.1001\/jamaneurol.2018.3692\n\n.","journal-title":"JAMA Neurology"},{"key":"4496_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151\u201362. \nhttps:\/\/doi.org\/10.1001\/jama.2018.12917\n\n.","journal-title":"JAMA."},{"key":"4496_CR24","doi-asserted-by":"crossref","unstructured":"American_Psychiatric_Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"4496_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. \nhttps:\/\/doi.org\/10.1016\/j.jalz.2011.03.008\n\n.","journal-title":"Alzheimers Dement"},{"key":"4496_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614-29. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0\n\n.","journal-title":"Lancet Neurol"},{"issue":"4","key":"4496_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jalz.2018.12.001","volume":"15","author":"Niklas Mattsson","year":"2019","unstructured":"Mattsson N, Insel PS, Donohue M, Jogi J, Ossenkoppele R, Olsson T, et al. Predicting diagnosis and cognition with (18)F-AV-1451 tau PET and structural MRI in Alzheimer\u2019s disease. Alzheimers Dement. 2019. \nhttps:\/\/doi.org\/10.1016\/j.jalz.2018.12.001\n\n.","journal-title":"Alzheimer's & Dementia"},{"key":"4496_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/mds.26813","volume":"32","author":"R Smith","year":"2017","unstructured":"Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hagerstrom D, et al. Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord. 2017;32:108\u201314. \nhttps:\/\/doi.org\/10.1002\/mds.26813\n\n.","journal-title":"Mov Disord"},{"key":"4496_CR29","doi-asserted-by":"publisher","unstructured":"Smith R, Scholl M, Londos E, Ohlsson T, Hansson O. F-18-AV-1451 in Parkinson\u2019s sisease with and without dementia and in dementia with Lewy bodies. Sci Rep-Uk. 2018;8. ARTN 4717. \nhttps:\/\/doi.org\/10.1038\/s41598-018-23041-x\n\n.","DOI":"10.1038\/s41598-018-23041-x"},{"key":"4496_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","volume":"89","author":"R Smith","year":"2017","unstructured":"Smith R, Scholl M, Widner H, van Westen D, Svenningsson P, Hagerstrom D, et al. In vivo retention of (18)F-AV-1451 in corticobasal syndrome. Neurology. 2017;89:845\u201353. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000004264\n\n.","journal-title":"Neurology."},{"key":"4496_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33\u20139.","journal-title":"Arch Neurol"},{"key":"4496_CR32","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853\u201364. \nhttps:\/\/doi.org\/10.1002\/mds.26987\n\n.","journal-title":"Mov Disord"},{"key":"4496_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670\u20136. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15\n\n.","journal-title":"Neurology."},{"key":"4496_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503. \nhttps:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1\n\n.","journal-title":"Neurology."},{"key":"4496_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314. \nhttps:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6\n\n.","journal-title":"Neurology."},{"key":"4496_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.116.174508","volume":"58","author":"A Hahn","year":"2017","unstructured":"Hahn A, Schain M, Erlandsson M, Sjolin P, James GM, Strandberg OT, et al. Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology. J Nucl Med. 2017;58:623\u201331. \nhttps:\/\/doi.org\/10.2967\/jnumed.116.174508\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR37","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.dib.2017.10.024","volume":"15","author":"SL Baker","year":"2017","unstructured":"Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief. 2017;15:648\u201357. \nhttps:\/\/doi.org\/10.1016\/j.dib.2017.10.024\n\n.","journal-title":"Data Brief"},{"key":"4496_CR38","first-page":"904","volume":"39","author":"OG Rousset","year":"1998","unstructured":"Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39:904\u201311.","journal-title":"J Nucl Med"},{"key":"4496_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247\u201358. \nhttps:\/\/doi.org\/10.1002\/ana.24711\n\n.","journal-title":"Ann Neurol"},{"key":"4496_CR40","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340. \nhttps:\/\/doi.org\/10.1097\/00004647-199609000-00008\n\n.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4496_CR41","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain. 2018;141:1517\u201328. \nhttps:\/\/doi.org\/10.1093\/brain\/awy059\n\n.","journal-title":"Brain."},{"key":"4496_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110\u20139. \nhttps:\/\/doi.org\/10.1002\/ana.24546\n\n.","journal-title":"Ann Neurol"},{"key":"4496_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971\u201382. \nhttps:\/\/doi.org\/10.1016\/j.neuron.2016.01.028\n\n.","journal-title":"Neuron."},{"key":"4496_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.116.175273","volume":"58","author":"SL Baker","year":"2017","unstructured":"Baker SL, Lockhart SN, Price JC, He M, Huesman RH, Schonhaut D, et al. Reference tissue-based kinetic evaluation of 18F-AV-1451 for tau imaging. J Nucl Med. 2017;58:332\u20138. \nhttps:\/\/doi.org\/10.2967\/jnumed.116.175273\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2967\/jnumed.116.182881","volume":"58","author":"O Barret","year":"2017","unstructured":"Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, et al. Kinetic modeling of the tau PET tracer (18)F-AV-1451 in human healthy volunteers and Alzheimer disease subjects. J Nucl Med. 2017;58:1124\u201331. \nhttps:\/\/doi.org\/10.2967\/jnumed.116.182881\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR46","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2967\/jnumed.115.170027","volume":"57","author":"S Shcherbinin","year":"2016","unstructured":"Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med. 2016;57:1535\u201342. \nhttps:\/\/doi.org\/10.2967\/jnumed.115.170027\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2967\/jnumed.117.195248","volume":"59","author":"JY Choi","year":"2018","unstructured":"Choi JY, Cho H, Ahn SJ, Lee JH, Ryu YH, Lee MS, et al. Off-target F-18-AV-1451 binding in the basal ganglia correlates with age-related iron accumulation. J Nucl Med. 2018;59:117\u201320. \nhttps:\/\/doi.org\/10.2967\/jnumed.117.195248\n\n.","journal-title":"J Nucl Med"},{"key":"4496_CR48","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00259-017-3876-0","volume":"45","author":"YK Jang","year":"2018","unstructured":"Jang YK, Lyoo CH, Park S, Oh SJ, Cho H, Oh M, et al. Head to head comparison of [(18)F] AV-1451 and [(18)F] THK5351 for tau imaging in Alzheimer\u2019s disease and frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2018;45:432\u201342. \nhttps:\/\/doi.org\/10.1007\/s00259-017-3876-0\n\n.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4496_CR49","unstructured":"Weimer RM, Barrett O, Tamagnan G, Alagille D, Marik J, Ayalon G, et al. Evaluation of baseline and longitudinal tau burden in Alzheimer\u2019s disease using [18F]GTP1 (Genentech Tau Probe 1) PET imaging. Human Amyloid Imaging Meeting. 2017:pp. 91."},{"key":"4496_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","volume":"97","author":"Michael Sch\u00f6ll","year":"2019","unstructured":"Scholl M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2018. \nhttps:\/\/doi.org\/10.1016\/j.mcn.2018.12.001\n\n.","journal-title":"Molecular and Cellular Neuroscience"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04496-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T19:34:52Z","timestamp":1602531292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04496-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4496"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04496-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]},"assertion":[{"value":"30 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AL, JJ, TO, and OS report no disclosures. RS has served as a (non-paid) consultant for Roche. MS has served on an advisory board for Servier. OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2\u00a0years, he has received consultancy\/speaker fees (paid to the institution) from Biogen and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the Regional ethics committee at Lund University, Sweden, and was in accordance with the Helsinki declaration. All imaging procedures were approved by the Radiation protection committee at Sk\u00e5ne University Hospital and by the Swedish Medical Products Agency.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}